Donnelly, Louise A. http://orcid.org/0000-0003-4902-1040
McCrimmon, Rory J. http://orcid.org/0000-0002-3957-1981
Pearson, Ewan R. http://orcid.org/0000-0001-9237-8585
Funding for this research was provided by:
Innovative Medicines Initiative 2 Joint Undertaking (875534)
Article History
Received: 9 February 2024
Accepted: 14 May 2024
First Online: 5 July 2024
Acknowledgements
: We acknowledge the support of the Health Informatics Centre, University of Dundee, in managing and supplying the anonymised data.
: The data that support the findings of this study are not openly available for reasons of sensitivity, but are available from the corresponding author upon reasonable request.
: This manuscript is part of the Stratification of Obesity Phenotypes to Optimise Future Obesity Therapy (SOPHIA) project (). SOPHIA has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 875534. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the EFPIA and T1D Exchange, JDRF and the Obesity Action Coalition. The communication reflects the authors’ views and neither the IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein.
: ERP has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Eli Lilly, Illumina and Sanofi, and support for attending meetings and/or travel from Eli Lilly. RJM has received honoraria for lectures and advisory boards for NovoNordisk and Sanofi. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: LAD designed the study and performed the analyses. All authors contributed to data interpretation and drafting of the manuscript. All authors critically revised the manuscript and approved the final version. ERP is the guarantor of this work.